Natco Pharma has received its board’s approval to raise Rs 1,500 crore through further issue of shares or convertible securities of any nature through one or more modes, including but not limited to a further public and private offerings, rights issue, qualified institutional placement, issue of American depository receipts or global depository receipts etc. The company’s board gave approval for the same at its meeting held on November 2, 2017.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
